A phase II trial to evaluate the safety, tolerability and efficacy of TG4010 in combination with nivolumab + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1

Trial Profile

A phase II trial to evaluate the safety, tolerability and efficacy of TG4010 in combination with nivolumab + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs TG 4010 (Primary) ; Nivolumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 11 Sep 2017 According to a Transgene media release, US FDA granted Investigational New Drug (IND) clearance to proceed with this trial and first patient is expected to be included into this Phase 2 study at the end of 2017.
    • 26 Apr 2017 New trial record
    • 25 Apr 2017 First results from this trial are expected in 2018, according to a Transgene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top